Endpoints News interviewed Johnson & Johnson's R&D chief John Reed about his strategy for drug development, acquisitions, obesity and cardiovascular disease.
John Reed, J&J EVP, Innovative Medicine, R&D (Jordan Strauss/Invision/AP)
June 29, 2026 01:51 PM EDT
John Reed on J&J’s R&D model, recent oncology deals and pipeline expansion potential
John Reed has overseen the pipelines of three of the largest drugmakers since leaving Southern California’s Sanford Burnham medical research institute 13 years ago, giving …
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
Johnson & Johnson said it will purchase the startup Firefly Bio for $1 billion in an effort to expand its work in the suddenly…
Johnson & Johnson is making another early-stage oncology deal, dishing out $1 billion in cash to acquire Firefly Bio, a…
Leerink analysts lifted J&J shares to a buy equivalent from hold on Wednesday, citing the company's slate of new drugs.
Johnson & Johnson to Acquire Firefly Bio, Inc. to Expand Oncology Pipeline with Novel Degrader Antibody Conjugate Platform
A closely watched therapy developed by Johnson & Johnson failed to show a statistically meaningful improvement for IBD patients.
With a new phase 3 win for Erleada (apalutamide), Johnson & Johnson is proposing a solution to a longstanding prostate cancer…
